Clinical trials: Glioblastoma, IDH-wildtype
Glioblastoma, Glioblastoma, IDH-wildtype
Biomolecular Analysis for Predicting Response to Regorafenib
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
- Trial name
- RegoRec (NCT05759195)
- Testing
- Biomolecular tumor analysis
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Primary Glioblastoma, Glioblastoma Multiforme
LAM561 With RT and TMZ for Adults With Glioblastoma
The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with…
- Trial name
- CLINGLIO (NCT04250922)
- Testing
- LAM561, TMZ, RT
- Where
- 22 sites in France, Israel and 3 more
- Volunteers
- 144 people
- Sponsor
- Laminar Pharmaceuticals
IDH Wildtype Glioblastoma, Glioblastoma (GBM)
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
This study will investigate whether rapid molecular testing of recurrent glioblastoma (GBM) can identify tumour biomarkers that may help guide treatment selection in younger people with IDH-wildtype GBM.
- Trial name
- BRAid GBM (NCT07908147)
- Testing
- Larotrectinib, Cadonilimab, Plixorafenib
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Glioblastoma, Glioblastoma Multiforme
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain
- Trial name
- RECSUR (NCT06283927)
- Testing
- Re-resection, Temozolomide, Lomustine
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 464 people
- Sponsor
- Jasper Gerritsen
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse…
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma
- Trial name
- NCT07468136
- Testing
- Biospecimen Collection, Eflornithine, Lumbar Puncture
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study
This prospective, interventional, monocentric study will aim at investigating the relationship between pesticide exposure and the treatment response of patients with GBM.
- Trial name
- EXPOGLIO (NCT07788430)
- Testing
- Biological sample collection, Self-reported questionnaire
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Claudius Regaud
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
IDH Wildtype Glioblastoma, IDH Mutant Lower-Grade Gliomas
Metabolomics and Transcriptomics of Low- and High-Grade Gliomas
The goal of this observational study is to better define the molecular profile of rare brain tumors (gliomas) based on the levels of their metabolites and transcripts (the intermediate step between DNA information and proteins).
- Trial name
- GlioMeTra (NCT07832734)
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Glioblastoma, IDH-wildtype
Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma
The study aims at: 1. Perform a multilayer analysis relying on tight integration of in-depth multi-omics approaches with clinical data to discover immune markers, with attention to age and sex differences, predicting prognosis…
- Trial name
- IPerGlioGEM (NCT05941234)
- Testing
- Biological biomarker analysis
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma.
- Trial name
- NCT07452458
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 54 sites in United States
- Volunteers
- 398 people
- Sponsor
- NRG Oncology
Brain Tumor, Recurrent, Glioblastoma Multiforme
A Phase I/II Study of the Photon Radiosurgery System
The standard treatment for children with brain tumors is surgical removal of the tumor followed by radiation to the brain and chemotherapy (medicines) given to shrink any remaining tumor or to prevent tumor from growing back.
- Trial name
- NCT00179907
- Testing
- Photon Radiosurgery System (Intrabeam)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Primary Glioblastoma
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Glioblastomas (GBM) are the most frequent brain tumors and one of the most lethal adult cancers despite maximal multimodal therapy.
- Trial name
- MATVAC-1 (NCT07347210)
- Testing
- UCPVax, Pembrolizumab, Temozolomide
- Where
- 4 sites in France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Glioblastoma, IDH-wildtype, Metformin
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies.
- Conditions
- Glioblastoma, IDH-wildtype, Metformin, Malignancies
- Trial name
- NCT05929495
- Testing
- Metformin
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Milano Bicocca
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
IDH-Wildtype Glioblastoma, Glioblastoma (GBM)
The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body change over a 24-hour cycle.
- Trial name
- TMZ-CHRONO (NCT06850766)
- Testing
- Morning administration of TMZ, Evening administration of TMZ
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Glioblastoma
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is associated with poor prognosis despite standard treatment with maximal safe resection followed by radiotherapy plus temozolomide (the Stupp…
- Trial name
- ELITE (NCT07758062)
- Testing
- Levetiracetam Extended-Release Granules, Temozolomide (TMZ), Radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Tianjin Medical University General Hospital
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Primary Glioblastoma
Carbon Ion Radiotherapy for Primary Glioblastoma
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons.
- Trial name
- CLEOPATRA (NCT01165671)
- Testing
- Carbon Ion Radiotherapy, Proton Radiotherapy
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Heidelberg